At a glance
A dual GLP-1 and glucagon receptor agonist studied in metabolic disease.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited studies address weight and liver-related outcomes. Their results require the original population, treatment period and adverse-event context.[1][2][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Survodutide.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Titration (2 mL = 5 mg/mL)
| Week | Weekly Dose (mg) | Weekly Dose (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 600 mcg | 12 units (0.12 mL) |
| Weeks 3–4 | 1.2 mg | 1200 mcg | 24 units (0.24 mL) |
| Weeks 5–6 | 1.8 mg | 1800 mcg | 36 units (0.36 mL) |
| Weeks 7–8 | 2.4 mg | 2400 mcg | 48 units (0.48 mL) |
| Weeks 9–10 | 3.6 mg | 3600 mcg | 72 units (0.72 mL) |
| Weeks 11–12 | 4.8 mg | 4800 mcg | 96 units (0.96 mL) |
| Week 13+ | 6.0 mg | 6000 mcg | 120 units (1.20 mL)* |
Route & Frequency: Subcutaneous injection once weekly (all clinical trials used weekly dosing)[1][2]. *Note: The 6.0 mg maintenance dose (120 units / 1.20 mL) exceeds a standard 100‑unit (1 mL) insulin syringe. Use a 1 mL or 3 mL Luer‑lock syringe with appropriate needle, or administer as two separate injections.
Additional schedule context & duration
Concise summary of the once‑weekly regimen.
- Goal: Support metabolic improvement and weight management through dual GLP‑1/glucagon receptor activation[1][3].
- Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as studied in phase 3 trials).
- Dose Range: 0.6–6.0 mg weekly with gradual titration over 10–12 weeks.
- Reconstitution: 2.0 mL per 10 mg vial (5 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; protect from light and avoid freeze–thaw.
Suggested weekly titration approach based on clinical trial designs[1][2].
- Start: 0.6 mg weekly; increase by 0.6 mg every 2 weeks as tolerated.
- Target: 4.8–6.0 mg weekly by weeks 11–13.
- Frequency: Once per week (subcutaneous).
- Cycle Length: 12–16 weeks minimum; phase 3 trials extend to 48–72 weeks.
- Timing: Same day each week; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at ≤−20 °C (≤−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); protect from light and avoid repeated freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[8].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week weekly protocol with gradual titration.
-
Peptide Vials (Survodutide, 10 mg each):
- 8 weeks ≈ 2 vials (~17 mg total)
- 12 weeks ≈ 4 vials (~39 mg total)
- 16 weeks ≈ 7 vials (~63 mg total)
-
Insulin Syringes (U‑100) or 1 mL Luer‑lock Syringes:
- Per week: 1 syringe (once weekly)
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
Obesity (Silver Spring) (2024) — Wharton et al. SYNCHRONIZE‑1 & 2 phase 3 trial design for survodutide in obesity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
- 07
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
MedlinePlus (NIH) — Giving an insulin injection: patient guide for subcutaneous technique (opens in a new tab)medlineplus.gov
Back to overview ↑ - 09
Public health resource
Veterans Affairs (2023) — Insulin injection: how to use and where to inject (injection sites, rotation guidance) (opens in a new tab)www.veteranshealthlibrary.va.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.